A.K.Byg ApS: Financial statements 2018
CVR: 37611123
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
A.K.Byg ApS (CVR 37611123) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -507,906 and a net result of DKK -510,182 compared with DKK -27,457 the year before. Equity in the 2018 report amounted to DKK -550,013.
- Gross Profit
- DKK -507,906
- Profit/Loss
- DKK -510,182
- Equity
- DKK -550,013
- Total Assets
- DKK 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -508 t. | -510 t. | -550 t. | - |
| 2017 | 0 | -27 t. | -27 t. | -40 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
A.K.Byg ApS has published its annual report for 2017. Revenue came to DKK 0, and the net result was DKK -27,457.
On May 24, 2018, the company changed its name from Heino Frederiksen Consulting IVS to Receptor Oncology IVS.
About A.K.Byg ApS
A.K.Byg ApS was a Danish company of the type Anpartsselskab based in Brøndby, founded in 2016. The company has been dissolved on 12 May 2023. The company was registered under the industry Murere. The company was previously named A.K.Byg IVS and Datoselskabet 5. juni IVS. In 2020, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK 0 the year before. Equity in the 2020 report amounted to DKK -550,013.